Biodexa Pharmaceuticals (BDRX) Short-Term Debt issuances (2020 - 2021)
Biodexa Pharmaceuticals (BDRX) posted Short-Term Debt issuances of -$140193.1 for Q4 2021, up 2.98% sequentially from -$144506.4 in Q3 2021, and up 96.59% YoY from -$71314.2 in Q4 2020.
Biodexa Pharmaceuticals (BDRX) Short-Term Debt issuances (2020 - 2021) Analysis & Trends
Biodexa Pharmaceuticals has reported Short-Term Debt issuances for 2 years, with the latest figure at -$140193.1 in Q4 2021.
- Quarterly Short-Term Debt issuances rose 96.59% year-over-year to -$140193.1 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$8.3 million (changed N/A YoY) and the FY2021 annual result came in at -$143091.4, changed N/A from the prior year.
- Short-Term Debt issuances advanced to -$140193.1 in Q4 2021 per BDRX's latest filing, from -$144506.4 in the prior quarter.
- Over five years, Short-Term Debt issuances peaked at -$140193.1 in Q4 2021 and troughed at -$4.1 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -140,193.10 |
| Dec 31, 2021 | -140,193.10 |
| Sep 17, 2021 | -144,506.43 |
| Sep 17, 2021 | -144,506.43 |
| Dec 31, 2020 | -4.11 Mn |
| Dec 31, 2020 | -4.11 Mn |
| Sep 10, 2020 | -3.92 Mn |
| Sep 10, 2020 | -3.92 Mn |